<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468232</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B1301</org_study_id>
    <nct_id>NCT02468232</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.</brief_title>
  <acronym>PARALLEL-HF</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of LCZ696 at a target dose of 200 mg b.i.d.
      compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF)
      treatment, on delaying time to first occurrence of either cardiovascular (CV) death or HF
      hospitalization events in Japanese patients with stable chronic heart failure (CHF), New York
      Heart Association (NYHA) classes II-IV and reduced ejection fraction (left ventricular
      ejection fraction (LVEF) ≤ 35%).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Anticipated">November 26, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first occurrence of the composite endpoint, which is defined as either cardiovascular (CV) death or heart failure (HF) hospitalization</measure>
    <time_frame>up to 40 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline at predefined time points</measure>
    <time_frame>Baseline, Weeks 4, 8 and Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of CV death, HF hospitalization or intensification of treatments due to documented episode(s) of worsening HF</measure>
    <time_frame>up to 40 months</time_frame>
    <description>Worsening HF defined as: worsening signs and symptoms of HF requiring addition of a new drug for HF treatment, initiation of IV treatment, increase of diuretic dose for persistent use for ≥4 consecutive weeks, or institution of mechanical or circulatory support such as mechanical ventilation, ultrafiltration, hemodialysis, intra-aortic balloon pump or ventricular assist device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association (NYHA) classification from baseline at predefined timepoints</measure>
    <time_frame>Baseline, Weeks 4, 8 and Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical summary score for heart failure symptoms and physical limitations from baseline</measure>
    <time_frame>Baseline, Week 8 and Month 6</time_frame>
    <description>Clinical summary score for heart failure symptoms and physical limitations will be assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with reported total adverse events, serious adverse events and death</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations</measure>
    <time_frame>up tp 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical composite score (as assessed by NYHA classification and patient global assessment) at predefined time point</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause mortality</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients hospitalized</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admission</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-hospitalization</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency visits for HF</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood NT-proBNP from baseline</measure>
    <time_frame>Baseline, Weeks 4, 8 and Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood amino-terminal propeptide of procollagen type III from baseline</measure>
    <time_frame>Baseline and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine cGMP from baseline</measure>
    <time_frame>Baseline, Weeks 4, 8 and Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction (HF-rEF)</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before randomization, all patients receive 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm will start with 100 mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 200 mg b.i.d. at week 4 if they are tolerant to 100 mg b.i.d. Total duration of treatment will be up to approximately 40 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In double blind period, all randomized patients in this arm will receive enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 10 mg b.i.d. at week 4 if they are tolerant to 5 mg b.i.d. Total duration of treatment will be up to approximately 40 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 50 mg, 100 mg, 200 mg film-coated tablets</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril 2.5 mg, 5 mg, 10 mg film-coated tablets</description>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to LCZ696</intervention_name>
    <description>Placebo to match LCZ696 50 mg, 100 mg and 200 mg film-coated tablets</description>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Enalapril</intervention_name>
    <description>Placebo to match enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Outpatients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction:

          -  LVEF ≤ 35% at Visit 1 (any local measurement, made within the past 6 months using
             echocardiography, MUGA, CT scanning, MRI or ventricular angiography is also
             acceptable, provided no subsequent measurement above 35%)

          -  NT-proBNP ≥ 600 pg/ml at Visit 1 OR NT-proBNP ≥ 400 pg/ml at Visit 1 and a
             hospitalization for HF within the last 12 months (according to central laboratory
             measurements)

          -  Patients must be on an ACEI or an ARB at a stable dose for at least 4 weeks before
             Visit 1.

          -  Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at
             a stable dose for at least 4 weeks prior to Visit 1 (reason should be documented if
             patients reported contraindications or intolerance).

          -  An aldosterone antagonist should also be considered in all patients, taking account of
             renal function, serum potassium and tolerability. If given, the dose of aldosterone
             antagonist should be optimized according to guideline recommendations and patient
             tolerability, and should be stable for at least 4 weeks prior to Visit 1. Other
             evidence-based therapy for HF should also be considered e.g. cardiac resynchronization
             therapy and an implantable cardioverter-defibrillator in selected patients, as
             recommended by guidelines.

        Exclusion Criteria:

          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes, ACEIs, ARBs, NEP inhibitors as well as known or suspected contraindications
             to the study drugs.

          -  Previous documented history of intolerance to ACEIs or ARBs.

          -  Known history of angioedema.

          -  Requirement of treatment with both ACEIs and ARBs.

          -  Current acute decompensated HF (exacerbation of chronic HF manifested by signs and
             symptoms that may require intravenous therapy).

          -  Symptomatic hypotension and/or a SBP &lt; 100 mmHg at screening or &lt; 95 mmHg at the end
             of run-in.

          -  Estimated GFR &lt; 30 mL/min/1.73 m2 as measured by the Japanese formula at screening, or
             the end of run-in or &gt; 35% decline in eGFR between screening and end of run-in
             (according to local measurements).

          -  Serum potassium &gt; 5.2 mmol/L (mEq/L) at screening or &gt; 5.4 mmol/L (mEq/L) at the end
             of run-in (according to local measurements).

          -  Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other
             major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty
             within the 3 months prior to Visit 1.

          -  Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months
             prior to Visit 1.

          -  Symptomatic bradycardia or second (except asymptomatic Wenckebach block) or third
             degree heart block without a pacemaker.

          -  Presence of hemodynamically significant mitral and/or aortic valve disease, except
             mitral regurgitation secondary to left ventricular dilatation.

          -  Presence of other hemodynamically significant obstructive lesions of left ventricular
             outflow tract, including aortic and sub-aortic stenosis.

          -  Presence of bilateral renal artery stenosis.

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seto-city</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chikushino-city</city>
        <state>Fukuka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iizuka-city</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurume-city</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukushima-city</city>
        <state>Fukushima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koriyama-city</city>
        <state>Fukushima</state>
        <zip>963-8052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hatsukaichi-city</city>
        <state>Hiroshima</state>
        <zip>738 8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Onomichi-city</city>
        <state>Hiroshima</state>
        <zip>722-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa-city</city>
        <state>Hokkaido</state>
        <zip>078-8211</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Otaru-city</city>
        <state>Hokkaido</state>
        <zip>047-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amagasaki-city</city>
        <state>Hyogo</state>
        <zip>660-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takarazuka-city</city>
        <state>Hyogo</state>
        <zip>665-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morioka-city</city>
        <state>Iwate</state>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takamatsu-city</city>
        <state>Kagawa</state>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uji-city</city>
        <state>Kyoto</state>
        <zip>611-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miyhazaki-city</city>
        <state>Miyazaki</state>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saku-city</city>
        <state>Nagano</state>
        <zip>3850051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashihara-city</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oita-city</city>
        <state>Oita</state>
        <zip>870-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kishiwada-city</city>
        <state>Osaka</state>
        <zip>596-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>559-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takatsuki-city</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyonaka-city</city>
        <state>Osaka</state>
        <zip>560-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama-city</city>
        <state>Saitama</state>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa-city</city>
        <state>Saitama</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kusatsu-city</city>
        <state>Shiga</state>
        <zip>525-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kakegawa-city</city>
        <state>Shizuoka</state>
        <zip>436-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka-city</city>
        <state>Shizuoka</state>
        <zip>420-8630</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Akishima-city</city>
        <state>Tokyo</state>
        <zip>196-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yonago-city</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shunan-city</city>
        <state>Yamaguchi</state>
        <zip>745-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kofu-city</city>
        <state>Yamanashi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic heart failure</keyword>
  <keyword>cardiovascular death</keyword>
  <keyword>hospitalization</keyword>
  <keyword>outcome study</keyword>
  <keyword>worsening heart failure</keyword>
  <keyword>NT-proBNP</keyword>
  <keyword>NYHA</keyword>
  <keyword>KCCQ</keyword>
  <keyword>HF-rEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

